Terapia de resincronización cardíaca. Evolución a largo plazo de los pacientes respondedores y no respondedores / Cardiac Resynchronization Therapy. Long-term Evolution of Responder and Non-responder Patients

RESUMEN Introducción: La terapia de resincronización cardíaca (TRC) es un tratamiento eficaz en pacientes con insuficiencia cardíaca (IC), baja fracción de eyección del ventrículo izquierdo (FEVI) y QRS ancho. Sin embargo, hay un porcentaje de estos que son no respondedores, lo que implicaría peores resultados clínicos. Objetivos: Valorar las diferencias en parámetros ecocardiográficos de remodelado reverso y tasa de eventos [hospitalización por insuficiencia cardíaca (HIC), muerte de todas las causas (MT), trasplante cardíaco (TXC) y terapias apropiadas (TA)] entre pacientes respondedores vs. no respondedores a la TRC. Material y métodos: Se incluyeron 343 pacientes con TRC. Se los clasifico en respondedores y no respondedores según parámetros clínicos y ecocardiográficos. Se realizó seguimiento a 2 años, en que se evaluó el remodelado reverso y la incidencia de HIC, MT, TXC y TA. Resultados: De los 343 pacientes, 17% fueron no respondedores y 83% respondedores. A los 6 meses y 12 meses no hubo diferencias significativas en cuando a diámetros ventriculares, pero si en la FEVI (p<0,001), que aumentó más en los respondedores. A los 24 meses los respondedores presentaron menor diámetro diastólico (p=0,004), menor diámetro sistólico (p=0,003) y mayor FEVI (p<0,001) Los no respondedores tuvieron significativamente mayor incidencia de HIC (p< 0,001), TXC (p=0,001) y TA (p=0,002) y un exceso de MT en el límite de la significación estadística (p= 0,056). Conclusiones: Los pacientes respondedores a la TRC presentaron mayor remodelado reverso y mejor evolución clínica, en forma acorde a los resultados de estudios observacionales internacionales.

ABSTRACT Background: Cardiac resynchronization therapy (CRT) is an effective treatment in patients with heart failure (HF), low left ventricular ejection fraction (LVEF) and wide QRS. However, there are a percentage of these patients who are non-responders, implying worse clinical outcomes. Objectives: The aim of this study was to assess the differences in echocardiographic parameters of reverse remodeling and event rates [hospitalization for heart failure (HHF), all-cause mortality (ACM), heart transplantation (HTX) and appropriate therapies (AT)] between responder vs. non-responder patients to CRT. Methods: A total of 343 patients with CRT, classified into responders and non-responders according to clinical and echocardiographic parameters, were included in the study. A 2-year follow-up was performed, in which reverse remodeling and the incidence of HHF, ACM, HTX and AT were evaluated. Results: Among the 343 patients, 17% were non-responders and 83% responders. At 6 and 12 months there were no significant differences in ventricular diameters, but significant differences in LVEF (p<0.001), with greater increase in responders. At 24 months, responders had smaller diastolic diameter (p=0.004), smaller systolic diameter (p=0.003) and higher LVEF (p<0.001). Non-responders had significantly higher incidence of HHF (p<0.001), HTX (p=0.001) and AT (p=0.002), and an excess of ACM at the limit of statistical significance (p= 0.056). Conclusions: Patients responding to CRT presented greater reverse remodeling and better clinical evolution, in accordance with the results of international observational studies.

Heart failure related cardiogenic shock: An ISHLT consensus conference content summary.

In recent years, there have been significant advancements in the understanding, risk-stratification, and treatment of cardiogenic shock (CS). Despite improved pharmacologic and device-based therapies for CS, short-term mortality remains as high as 50%. Most recent efforts in research have focused on CS related to acute myocardial infarction, even though heart failure related CS (HF-CS) accounts for >50% of CS cases. There is a paucity of high-quality evidence to support standardized clinical practices in approach to HF-CS. In addition, there is an unmet need to identify disease-specific diagnostic and risk-stratification strategies upon admission, which might ultimately guide the choice of therapies, and thereby improve outcomes and optimize resource allocation. The heterogeneity in defining CS, patient phenotypes, treatment goals and therapies has resulted in difficulty comparing published reports and standardized treatment algorithms. An International Society for Heart and Lung Transplantation (ISHLT) consensus conference was organized to better define, diagnose, and manage HF-CS. There were 54 participants (advanced heart failure and interventional cardiologists, cardiothoracic surgeons, critical care cardiologists, intensivists, pharmacists, and allied health professionals), with vast clinical and published experience in CS, representing 42 centers worldwide. State-of-the-art HF-CS presentations occurred with subsequent breakout sessions planned in an attempt to reach consensus on various issues, including but not limited to models of CS care delivery, patient presentations in HF-CS, and strategies in HF-CS management. This consensus report summarizes the contemporary literature review on HF-CS presented in the first half of the conference (part 1), while the accompanying document (part 2) covers the breakout sessions where the previously agreed upon clinical issues were discussed with an aim to get to a consensus.

Endomyocardiofibrosis in the Americas Collaborative Study: The EMF-SIAC Registry.

Endomyocardiofibrosis (EMF) is a restrictive cardiomyopathy characterized by subendocardial fibrosis due to eosinophilic myocardial infiltration. EMF may commonly present with heart failure (HF) or atrial fibrillation (AF). Immunosuppression can be effective in early stages, but not in the chronic phase. Our objective was to describe the characteristics of EMF patients in the Americas. This registry is a retrospective multicenter cross-sectional study including patients ≥18 years-old with EMF diagnosed by imaging methods, according to the Mocumbi criteria. Clinical, biochemical, and imaging variables were analyzed. On the 54 patients included, 28 (52%) were male with an age of 47 years. The etiology was idiopathic in 47 (87%) patients, familial in 4 (7%), and secondary to chemotherapy in 2 (3.5%). We detected a history of HF in 41 patients (76%), AF in 19 (35%), and ischemic stroke in 8 (15%). The diagnosis was made by echocardiography in all patients, and 38% had Cardiac Resonance or Computed Tomography. Thirty-five patients (65%) presented a left ventricular ejection fraction ≥50%, 11 (21%) severe mitral regurgitation, and 18 (33%) severe tricuspid regurgitation. In 17 patients (32%) the diagnosis was confirmed by endomyocardial biopsy. Among medical therapy, 72% received beta-blockers, 63% vasodilators, 65% mineralocorticoid antagonists, 7.4% SGLT2 inhibitors, and 11% corticosteroids. Subendocardial resection was performed in 9 (16%) patients and mitral valve replacement in 11 (20%) patients. In conclusion, EMF patients had a high prevalence of HF, AF, and embolic events. The diagnosis was frequently made in an advanced stage when HF management and surgery were the only effective treatments.

Evidence of Continued CD4+ and CD8+ T Cell Activity After SARS-COV-2 Clearance in a Late COVID-19 Pneumonia Heart Transplant Patient.

We have studied an unvaccinated heart transplant 64-year-old patient admitted for low-grade fever, dry cough, general malaise, and bilateral interstitial infiltrates, after two months of a diagnosis of coronavirus disease 2019 (COVID-19) bilateral pneumonia. A bronchoalveolar lavage and transbronchial biopsy were performed. Bacterial, mycotic and viral infections were ruled out including repeated reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diffuse thickening of alveolar septa with fibrosis and infiltration of lymphocytes and macrophages into the alveolar septa with aggregates of CD4+ and CD8+ T cells with positive immunolabelling for granzyme B were observed, indicating a continuing cytotoxic process that might have induced proliferation and fibrosis. An intense ongoing immunopathological cellular reaction, potentially triggered by SARS-CoV-2 overcoming the anti-inflammatory and immunomodulatory effects of the immunosuppressive drugs is suggested by these findings, opening to debate the usual approach of minimizing immunosuppression after COVID-19 in transplant patients when presence of SARS-CoV-2 has been ruled out.

Trasplante cardíaco en miocardiopatía chagásica: 23 años de experiencia en un centro de referencia / Heart Transplantation in Chagas Cardiomyopathy: 23-Year Follow-Up in a Referral Center

RESUMEN Introducción: La enfermedad de Chagas afecta aproximadamente a 6 millones de personas en América Latina. El 25 a 35% evoluciona hacia la Miocardiopatía Chagásica (MCh). Una opción terapéutica en sus estadios avanzados es el trasplante cardíaco (TxC). Objetivos: Comparar la supervivencia de pacientes con TxC por MCh frente a otras etiologías. Analizar la incidencia de la reactivación (Ra) de enfermedad de Chagas y su impacto en la supervivencia en este subgrupo de pacientes. Material y métodos: Se evaluaron retrospectivamente pacientes con TxC entre agosto 1998 y marzo 2021. Se analizó la supervivencia mediante curvas de Kaplan-Meier y log rank test. El diagnóstico de Ra se realizó mediante métodos moleculares, prueba de Strout en sangre periférica, tejido miocárdico y/o cutáneo. Resultados: De 606 pacientes con TxC, 39 (6,4%) presentaban MCh. Seguimiento medio 4,4 años (Rango Intercuartilo 1,2-8,6). Edad subgrupo MCh 51 años (RIC 45-60). Hombres 28 (72%). Se documentó Ra en el 38,5% de los pacientes. Supervivencia a 1, 5 y 10 años en TxC por MCh con Ra versus no Ra: 85%, 76% y 61% versus 72%, 55% y 44% (p = 0,3). Supervivencia a 1, 5 y 10 años en TxC por MCh versus TxC por otras causas: 79%, 65% y 50% versus 79%, 62% y 47% (p = 0,5). Conclusión: En nuestra serie no se encontró diferencia estadísticamente significativa en la supervivencia de los pacientes trasplantados cardíacos por MCh en comparación con aquellos trasplantados por otras causas; así como tampoco entre los pacientes que reactivaron la enfermedad de Chagas y los que no lo hicieron.

ABSTRACT Background: Chagas disease affects about 6 million people in Latin America, and 25 to 35% progress to Chagas cardiomyopathy (ChCM). Heart transplantation (HTx) is a therapeutic option in advanced stages. Objectives: The aim of this study is to compare survival of patients with HTx due to ChCM versus those transplanted for other etiologies and to analyze the incidence of Chagas disease reactivation (Ra) and its impact on survival in this group of patients. Methods: Patients undergoing HTx between August 1998 and March 2021 were retrospectively evaluated. Survival was analyzed using Kaplan-Meier curves and the log-rank test. The diagnosis of Ra was performed by molecular methods, Strout's test in peripheral blood, myocardial tissue or skin tissue. Results: Of 606 patients with Htx, 39(6,4%) presented ChCM. Median follow up was 4.4 years (interquartile range 1.2-8.6). Median age of the subgroup with ChCM was 51 years (IQR 45-60) and 28 were men (72%). Reactivation was documented in 38.5% of the patients. Survival at 1, 5 and 10 years in HTx recipients due to ChCM and Ra versus no Ra was 85%, 76% and 61% versus 72%, 55% and 44%, respectively (p = 0.3). Survival at 1, 5 and 10 years in HTx recipients due to ChCM versus HTx for other causes was 79%, 65% and 50% versus 79%, 62% and 47%, respectively (p = 0.5). Conclusion: In our series we did not find statistically significant differences in survival of heart transplant recipients due to ChCM versus those transplanted due to other reasons. Survival in patients with Chagas disease reactivation and those without reactivation was also similar.

[Ischemic cardiogenic shock and short-term mechanical circulatory support as bridge to transplantation]. / Shock cardiogénico en infarto agudo de miocardio y soporte circulatorio puente al trasplante.

Cardiogenic shock (CS) has a high mortality rate and often requires advanced therapies such as mechanical circulatory support (MCS) and heart transplantation (HT). Those patients who presented an acute myocardial infarction (AMI) with CS and required support through MCS as bridge to HT were retrospectively analyzed in a single Center. Between January 1997 and June 2020, 524 patients received HT, 203 for ischemic-cardiomyopathy, 103 were in emergency waiting list. Eleven patients met the inclusion criteria (mean age 53 ± 11 years old; men 73%). Five primary angioplasties and 2 emergency myocardial revascularization surgeries were performed. Four patients had coronary anatomy not subject to revascularization. All received inotropic and vasopressor treatment and required intra-aortic balloon pump (IABP). Subsequently, two required support with a left univentricular centrifugal pump (BioMedicus®, Medtronic) and two with peripheral veno-arterial extracorporeal membrane oxygenator (VA-ECMO) (Maquet®, Getinge Group). The median between AMI and HT was 15 days (range 7-21) and the mean age of the donors 28 ± 11 years. All had extensive AMI (necrotic amount 35 ± 5%) with histopathological signs of transmural necrosis and reperfusion injury. The median follow-up was 9 years (range 1-15). None died in hospitalization or during the first year after transplantation. Survival at 5 and 10 years was 73% and 55%. Emergency HT may be the best option for selected patients with acute myocardial infarction and cardiogenic shock refractory to conventional therapy.

El shock cardiogénico (SC) presenta una elevada mortalidad y puede requerir de terapéuticas avanzadas como la asistencia circulatoria mecánica (ACM) y el trasplante cardíaco (TC). Se analizaron en forma retrospectiva, en un único centro, aquellos pacientes que presentaron un infarto agudo de miocardio (IAM), SC y requirieron ACM puente al TC. Entre enero 1997 y junio 2020, 524 pacientes recibieron un TC, 203 por cardiopatía isquémica, 103 en lista de emergencia. Se incluyeron once pacientes con los criterios mencionados (edad media 53 ± 11 años; hombres 73%). Se realizaron 5 angioplastias primarias y 2 cirugías de revascularización miocárdica de urgencia. Cuatro pacientes presentaban anatomía coronaria no pasible de revascularización. Todos recibieron tratamiento inotrópico y vasopresor y requirieron soporte con balón de contrapulsación intra aórtico (BCIA). Dos requirieron el implante de bomba centrífuga univentricular izquierda (BioMedicus®, Medtronic) y 2 de oxigenador de membrana extracorpóreo veno-arterial (ECMO-VA) periférico (Maquet®, Getinge Group). La mediana entre IAM y TC fue 15 días (rango 7-21) y la edad de los donantes 28 ± 11 años. Todos presentaron un IAM extenso (monto necrótico 35 ± 5%) con signos histopatológicos de necrosis transmural e injuria de reperfusión. La mediana de seguimiento fue 9 años (rango 1-15). Ninguno falleció en la internación ni durante el primer año post trasplante. La supervivencia a los 5 y 10 años fue 73% y 55%. El TC en situación de emergencia ha demostrado ser, en nuestro medio, la mejor opción en aquellos pacientes con IAM y SC refractario a la terapia convencional.

Shock cardiogénico en infarto agudo de miocardio y soporte circulatorio puente al trasplante / Ischemic cardiogenic shock and short-term mechanical circulatory support as bridge to Transplantation

Resumen El shock cardiogénico (SC) presenta una elevada mortalidad y puede requerir de terapéuticas avanzadas como la asistencia circulatoria mecánica (ACM) y el trasplante cardíaco (TC). Se analizaron en forma retrospectiva, en un único centro, aquellos pacientes que presentaron un infarto agudo de miocardio (IAM), SC y requirieron ACM puente al TC. Entre enero 1997 y junio 2020, 524 pacientes recibieron un TC, 203 por cardiopatía isquémica, 103 en lista de emergencia. Se incluyeron once pacientes con los criterios mencionados (edad media 53 ± 11 años; hombres 73%). Se realizaron 5 angioplastias primarias y 2 cirugías de revascularización miocárdica de urgencia. Cuatro pacientes presentaban anatomía coronaria no pasible de revascularización. Todos recibieron tratamiento inotrópico y vasopresor y requirieron soporte con balón de contrapulsación intra aórtico (BCIA). Dos requirieron el implante de bomba centrífuga univentricular izquierda (BioMedicus®, Medtronic) y 2 de oxigenador de membrana extracorpóreo veno-arterial (ECMO-VA) periférico (Maquet®, Getinge Group). La mediana entre IAM y TC fue 15 días (rango 7-21) y la edad de los donantes 28 ± 11 años. Todos presentaron un IAM extenso (monto necrótico 35 ± 5%) con signos histopatológicos de necrosis transmural e injuria de reperfusión. La mediana de seguimiento fue 9 años (rango 1-15). Ninguno falleció en la internación ni durante el primer año post trasplante. La supervivencia a los 5 y 10 años fue 73% y 55%. El TC en situación de emergencia ha demostrado ser, en nuestro medio, la mejor opción en aquellos pacientes con IAM y SC refractario a la terapia convencional.

Abstract Cardiogenic shock (CS) has a high mortality rate and often requires advanced therapies such as mechanical circulatory support (MCS) and heart transplantation (HT). Those patients who presented an acute myocardial infarction (AMI) with CS and required support through MCS as bridge to HT were retrospectively analyzed in a single Center. Between January 1997 and June 2020, 524 patients received HT, 203 for ischemic-cardiomyopathy, 103 were in emergency waiting list. Eleven patients met the inclusion criteria (mean age 53 ± 11 years old; men 73%). Five primary angioplasties and 2 emergency myocardial revasculariza tion surgeries were performed. Four patients had coronary anatomy not subject to revascularization. All received inotropic and vasopressor treatment and required intra-aortic balloon pump (IABP). Subsequently, two required support with a left univentricular centrifugal pump (BioMedicus®, Medtronic) and two with peripheral veno-arterial extracorporeal membrane oxygenator (VA-ECMO) (Maquet®, Getinge Group). The median between AMI and HT was 15 days (range 7-21) and the mean age of the donors 28 ± 11 years. All had extensive AMI (necrotic amount 35 ± 5%) with histopathological signs of transmural necrosis and reperfusion injury. The median follow-up was 9 years (range 1-15). None died in hospitalization or during the first year after transplantation. Survival at 5 and 10 years was 73% and 55%. Emergency HT may be the best option for selected patients with acute myocardial infarction and cardiogenic shock refractory to conventional therapy.

Primer implante exitoso de asistencia ventricular izquierda HeartMate 3TM como terapia de destino en Argentina. Revisión de la literatura / First successful Heartmate 3TM left ventricular assist device implantation as destination therapy in Argentina

RESUMEN Se presenta el primer implante exitoso de asistencia ventricular izquierda como terapia de destino mediante el dispositivo de flujo continuo centrífugo con levitación magnética intracorpóreo HeartMate 3TM (Abbott) en la Argentina. El dispositivo se implantó en una paciente de 52 años portadora de miocardio no compacto con disfunción ventricular izquierda grave, hipertensión pulmonar, insuficiencia cardíaca avanzada en estadio INTERMACS 3 y contraindicación para trasplante cardíaco debido a títulos elevados de anticuerpos preformados contra el sistema HLA en crossmatch contra panel.

ABSTRACT First case of successful implantation of intracorporeal full magnetically levitated continuous centrifugal flow left ventricular assist device HeartMate 3 Abbott® as destination therapy in Argentina in a female patient, 52-years-old with non compaction cardiomyopathy, severe left ventricular dysfunction, pulmonary hypertension, end-stage heart failure INTERMACS 3 and contraindication for heart transplantation due to high titers of preformed antibodies against the HLA system in panel reactive antibody assay.

Radiofrequency ablation of supraventricular arrhythmias after orthotopic heart transplantation: Long-term follow-up of a single-center experience.

BACKGROUND: Supraventricular arrhythmias (SVAs), commonly managed with radiofrequency ablation (RFA), may occur after orthotopic heart transplantation (OHT). METHODS: We retrospectively assessed 514 consecutive patients (pts.) undergoing OHT between January 1990 and July 2016 in a single-center. Patients with SVAs managed with RFA were included. Mechanisms of genesis of SVAs, association with surgical techniques and outcomes, were analyzed. RESULTS: Of 514 pts undergoing OHT, 53% (272 pts.) were managed with bicaval (BC) technique and 47% (242 pts.) with biatrial (BA) technique. Mean follow-up 10 ± 8.4 years. Nine pts. (1.7%) developed SVA requiring RFA. The BC technique was performed in 4 pts., 3 pts. presented cavotricuspid isthmus-dependent atrial flutter (CTI AFL), and 1 pt. double loop AFL. Five pts. were managed with BA technique, 4 pts. presented CTI AFL, and 1 pt. atrial tachycardia (AT). Mean time between OHT and SVA occurrence was 6.6 ± 5.5 years. The procedure was successful in 89% (8 pts.). Arrhythmia recurrence was seen in 3 pts (37%), all with BA technique. CONCLUSION: Supraventricular arrhythmias in heart transplantation may be associated with the surgical scar. Identifying the mechanism is vital to choose the appropriate treatment with radiofrequency ablation.

Intravascular ultrasound for cardiac allograft vasculopathy detection.

Cardiac allograft vasculopathy (CAV) after heart transplantation is a fibro-proliferative process affecting coronary arteries of the graft in up to 46.8% of the cases during the first 10 years post-transplantation. It is one of the main causes of graft loss and death. Due to graft denervation, CAV causing ischemia is usually clinically silent until the disease is far advanced. In this study, we compared coronary angiography with intravascular ultrasound (IVUS) for CAV detection. OUTCOMES: A total of 114 patients with HTx who underwent coronary angiography and IVUS between March 2018 and March 2019 were included. Mean follow-up was 87 ± 61 month. Lesions documented by coronary angiography were found in only 27 (24%) of the 114 patients. IVUS revealed ISHLT CAV 0 in 87 patients (76.3%); ISHLT CAV1 in 15 (13,1%) and ISHLT CAV2 and CAV3 in 6 patients (5.2%) each. Among 328 IVUS images, maximum intimal thickness (MIT) >0.5 mm was obtained in 60 vessels (52%) with 24 patients having three-vessel and 19 two-vessel involvement. CONCLUSION: As an adjunct to conventional coronary angiography to detect angiographically silent CAV in heart transplant patients, IVUS is a reliable and safe technique with a low complication rate. Large multicenter studies are necessary to confirm these findings and the potential long-term clinical impact of early detection in clinically and angiographically silent phase.

Short-term mechanical circulatory support devices as bridge to heart transplantation: A prospective single-center experience in Argentina.

BACKGROUND: Patients with cardiogenic shock may require hemodynamic stabilization with short-term mechanical circulatory support devices (ST-MCS) such as extracorporeal membrane oxygenation (ECMO) and centrifugal pump (CP) as bridge to transplantion (BTT). This study aimed to describe ECMO and CP during BTT and after heart transplant. METHODS: A cohort of patients on ECMO or CP as BTT between April 2006 and April 2018 in a single hospital. RESULTS: Thirty-seven consecutive patients with ECMO (n = 14) or CP (n = 23) were included. Acute kidney injury was more prevalent during CP (28.6% vs 69.6%, P = .02). There were no differences in stroke, thrombosis, sepsis, or vasoplegia. Bleeding (0% vs 56.5%, P = .0003) and reoperation (0% vs 47.8%, P = .002) were more frequent in CP group as well as mortality (0 vs 7 [30.4%], P = .03). The remaining 30 patients (81.1%) underwent heart transplantation, without differences in primary graft dysfunction, vasoplegia, reoperation for bleeding, or hospital stay. Mortality was 23.3% at 30 days, similar in both groups, with no further deaths at median follow-up of 44.2 months. CONCLUSIONS: In patients with cardiogenic shock, ST-MCS with ECMO or CP as BTT are a lifesaving approach allowing successful transplantation in the majority of cases, with good short- and long-term survival.

Realidad de la cirugía cardíaca en la República Argentina: Registro CONAREC XVI / Real Facts in Cardiovascular Surgery in Argentina. The XVI CONAREC Registry

Introducción Los dos grandes registros multicéntricos de cirugía cardíaca realizados en la Argentina, CONAREC y ESMUCICA, datan de más de 10 años. Considerando los avances médicos y quirúrgicos de la última década, surgió la necesidad de realizar un nuevo registro nacional, prospectivo y multicéntrico para conocer las características, la evolución, las complicaciones y los predictores de mortalidad de los pacientes sometidos a cirugía cardíaca. Objetivos Conocer el perfil epidemiológico, la modalidad quirúrgica y la evolución posoperatoria de los pacientes sometidos a cirugía cardíaca en la Argentina. Material y métodos Registro prospectivo, consecutivo y multicéntrico realizado en 49 centros cardioquirúrgicos de la República Argentina por residentes de cardiología. Se analizaron las características y la evolución de 2.553 pacientes sometidos a cirugía cardíaca entre septiembre de 2007 y octubre de 2008: 1.465 (57,4%) a cirugía coronaria, 359 (14,1%) a reemplazo valvular aórtico, 169 (6,6%) a cirugía valvular mitral, 312 (12,2%) a cirugía combinada coronariovalvular y 248 (9,7%) a otros procedimientos. Resultados Hubo predominio de hombres (74,9%); la edad promedio fue de 63 ± 11 años. La prevalencia de diabetes fue del 24,9%, la de hipertensión del 76,3% y la de insuficiencia cardíaca del 17%. La disfunción ventricular moderada a grave prequirúrgica fue del 23,8% y el 19,8% de las cirugías fueron no programadas. En las cirugías coronarias, el 41,9% de ellas se realizaron sin circulación extracorpórea y se empleó puente mamario en el 89%. El 81,7% de las cirugías mitrales se indicaron por insuficiencia y el 62,6% de las aórticas, por estenosis. En estas cirugías se emplearon válvulas mecánicas en el 58% de los casos. La mediana de internación fue de 6 días. Se presentaron complicaciones mayores en el 31,7% (del 25% en coronarios al 49,36% en combinados) y la mortalidad global fue del 7,7% (del 4,3% en coronarios al 13,4% en combinados). Conclusiones Este registro muestra la realidad de la cirugía cardíaca en centros con residencia o concurrencia de cardiología. Comparadas con cifras de registros nacionales previos, la mortalidad y las complicaciones mayores han disminuido, pero continúan siendo elevadas.

Background The CONAREC and the ESMUCICA studies are the largest multicenter registries performed in Argentina more than 10 years ago. The clinical and surgical advances achieved during the last decade have obliged us to carry out a new national, prospective and multicenter registry to become aware of the characteristics, outcomes, complications and predictors of mortality of patients undergoing cardiac surgery. Objectives To recognize the epidemiologic profile, surgical approach and postoperative outcomes of patients undergoing cardiac surgery in Argentina. Material and Methods This is a prospective, consecutive and multicenter registry performed by residents in Cardiology in 49 centers with cardiovascular surgery facilities. A total of 2553 patients undergoing cardiac surgery were included between September 2007 and October 2008, distributed as follows: coronary artery bypass graft surgery, 1465 patients (57.4%); aortic valve replacement, 359 (14.1%); mitral valve surgery, 169 (6.6%); combined procedure (revascularization-valve surgery), 312 (12.2%); other procedures, 248 (9.7%). Results There were more men (74.9%) than women; mean age was 63±11 years. The prevalence of diabetes was 24.9%, of hypertension 76.3% and of heart failure 17%. Preoperative moderate to severe left ventricular dysfunction was 23.8%, and 19.8% of surgeries were done on an urgent or emergency basis. A 41.9% of coronary artery bypass graft surgeries were done without cardiopulmonary bypass and a mammary artery bypass graft was used in 89%. Mitral valve surgery was indicated due to mitral regurgitation in 81.7% of cases and 63.6% of aortic valve surgeries were due to aortic valve stenosis. Mechanical heart valve prostheses were used in 58% of cases. Patients were hospitalized for a median of 6 days. Major complications occurred in 31.7% of cases (25% in revascularization surgeries and 49.36% in combined procedures) and global mortality was 7.7% (4.3% and 49.36%, respectively). Conclusions This registry demonstrates the real facts in cardiovascular surgery in centers with cardiovascular residents in Cardiology. Mortality and major complications are lower than those reported by previous registers, yet they are still high.